Becknam-Ref Vrednosti

AU reagent quick reference guide.
Reliable results, enhanced productivity.

Blood Banking
AU Clinical Chemistry Systems Centrifugation
Chemistry
Flow Cytometry
Hematology
Hemostasis
Immunoassay
Information Systems
Lab Automation
Molecular Diagnostics
Rapid Diagnostics
BR-13843A Not for distribution in the U.S.

T he precision specifications for the AU reagents listed in this document represent
the minimum levels of performance the tests are designed to meet for total precision.
These specifications do not represent typical performance, typical performance
is significantly better.
The measuring points listed in this document are the photometric time points the
software uses to calculate a result for each assay.
References to AU2700 listed in this document are also applicable to AU2700plus. If you
require additional information regarding any of the assays, please consult each individual
chemistry’s Instructions for Use (IFU) and analyzer-specific setting sheet.
Table of Contents
General Chemistry Esoterics
Alanine Aminotransferase (ALT)............................................................4 Cholinesterase (CHE)........................................................................... 27
Albumin (ALB)............................................................................................4 Creatine Kinase MB (CK-MB)............................................................ 27
Alkaline Phosphatase GSCC (ALP)....................................................5 D-Dimer (DDIM)..................................................................................... 27
Alkaline Phosphatase IFCC (ALP).......................................................5 Hemoglobin A1c (IFCC) (HbA1c)...................................................... 28
Amylase (CNP63) (AMY)........................................................................6 Lactate (LAC).......................................................................................... 28
Amylase (IFCC-EPS) (AMY) ................................................................6
Aspartate Aminotransferase (AST)......................................................6
Bicarbonate (CO2)...................................................................................7 Therapeutic Drug Monitoring (TDM)
Calcium Arsenazo (CALA)......................................................................7 Carbamazepine (CBZ).......................................................................... 29
Calcium oCPC (CA).................................................................................7 Digitoxin (DGT)....................................................................................... 29
Cholesterol (CHOL).................................................................................8 Digoxin (DIG)........................................................................................... 29
Cholesterol (CHOL).................................................................................8 Gentamicin (GENT)............................................................................... 30
Creatinine (CRE).......................................................................................8 Paracetamol (PARA)............................................................................. 30
Creatinine Enzymatic (CREZ)................................................................9 Phenobarbital (PHB)............................................................................. 30
Creatine Kinase (CK)...............................................................................9 Phenytoin (PHT)..................................................................................... 31
Direct Bilirubin (DBIL)........................................................................... 10 Theophylline (THEO)............................................................................. 31
Gamma-Glutamyltransferase (GGT)................................................ 10 Valproic Acid (VPA)............................................................................... 31
Glucose (GLU).........................................................................................11
Glucose (GLU-S)....................................................................................11
HDL Cholesterol (HDL-C)....................................................................11 Drugs of Abuse Testing (DAT)
Hydroxybutyrate Dehydrogenase (HBDH).......................................12 Amphetamines/Ecstasy 500 μg/L (AMP)........................................ 32
Iron (IRON)................................................................................................12 Amphetamines/Ecstasy 1000 μg/L (AMP)...................................... 32
LDL Cholesterol (LDL-C)......................................................................12 Amphetamines/Ecstasy SQ (AMP)................................................... 32
Lactate Dehydrogenase (IFCC) (LDH)............................................ 13 Barbiturate 200 μg/L (BAR)................................................................ 33
Lactate Dehydrogenase (SCE) (LDH26)......................................... 13 Barbiturate 300 μg/L (BAR)................................................................ 33
Lipase (LIP).............................................................................................. 13 Barbiturate SQ (BAR)........................................................................... 33
Magnesium (MG).....................................................................................14 Benzodiazepine 200 μg/L (BNZ)....................................................... 34
Phosphorus, Inorganic (PHOS)..........................................................14 Benzodiazepine 300 μg/L (BNZ)....................................................... 34
Total Bilirubin (TBIL)...............................................................................14 Benzodiazepine SQ (BNZ).................................................................. 34
Total Protein (TP).................................................................................... 15 Cocaine 150 μg/L (COC).................................................................... 35
Triglyceride (TRIG)................................................................................. 15 Cocaine 300 μg/L (COC).................................................................... 35
Unsaturated Iron Binding Capacity (UIBC)..................................... 16 Cocaine SQ (COC)............................................................................... 35
Unsaturated Iron Binding Capacity (UIBC)..................................... 16 EDDP 100 μg/L (EDDP)....................................................................... 36
Urea (UREA).............................................................................................17 EDDP SQ (EDDP)................................................................................. 36
Urea STAT (UREAS)...............................................................................17 Methadone 300 μg/L (MTD)............................................................... 37
Uric Acid (UA)..........................................................................................17 Methadone SQ (MTD).......................................................................... 37
Urinary/CSF Protein (UCSFP)............................................................ 18 Opiates 300 μg/L (OPI)....................................................................... 38
Opiates SQ (OPI).................................................................................. 38
THC 25 μg/L (THC).............................................................................. 39
Proteins/Serology THC 50 μg/L (THC).............................................................................. 39
Alpha-1-Acidglycoprotein (AAG)....................................................... 19 THC SQ (THC)....................................................................................... 39
Alpha -1-Antitrypsin (AAT)................................................................... 19
Anti-Streptolysin O (ASO)................................................................... 19
Apolipoprotein A1 (APO A1)............................................................... 20
Apolipoprotein B (APO B)................................................................... 20
Beta-2 Microglobulin (B2M)................................................................ 20
Ceruloplasmin (CER)............................................................................ 21
Complement 3 (C3)............................................................................... 21
Complement 4 (C4)............................................................................... 21
C-Reactive Protein (CRP)................................................................... 22
C-Reactive Protein (CRPN)................................................................ 22
C-Reactive Protein, High Sensitivity (CRPHS).............................. 22
Ferritin (FERR)........................................................................................ 23
Ferritin (FERR)........................................................................................ 23
Haptoglobin (HAPT).............................................................................. 23
Immunoglobulin A (IgA)........................................................................ 24
Immunoglobulin G (IgG)....................................................................... 24
Immunoglobulin M (IgM)....................................................................... 24
Microalbumin (MALB)........................................................................... 25
Myoglobin (MYO)................................................................................... 25
Prealbumin (PALB)................................................................................ 25
Rheumatoid Factor (RF)....................................................................... 26
Transferrin (TRF)..................................................................................... 26
General Chemistry
Alanine Aminotransferase
Chemistry Name Albumin
(IFCC)
Chemistry Abbreviation ALT ALB
Measurement Principle IFCC (with/without pyridoxal BCG
Phosphate Activation)
Reaction Type Rate End
Primary Wavelength 340 nm 600 nm
Measuring Points 14, 27 0, 1
Sample Type Serum/Plasma Serum/Plasma
Sample Size (AU400/AU600/AU640)
Serum/Plasma 10 μL (Pediatric: 10 μL) 2 μL (Pediatric: 2 μL)
Urine N/A N/A
CSF N/A N/A
Sample Size (AU480/AU680/
AU2700/AU5400)
Serum/Plasma 5 μL (Pediatric: 5 μL) 1.6 μL (Pediatric: 1.6 μL)
Urine N/A N/A
CSF N/A N/A
Reference Interval SI Units SI Units
Serum/Plasma Male: Male: Adults: Adults:

< 50 U/L < 0.85 μkat/L 3.5-5.2 g/dL 35-52 g/L
Female: Female: Newborn 0–4 days: Newborn 0–4 days:
< 35 U/L < 0.6 μkat/L 2.8-4.4 g/dL 28-44 g/L
Infant: Infant:
13-45 U/L 0.22-0.75 μkat/L
Urine N/A N/A N/A N/A
CSF N/A N/A N/A N/A
Analytical Range SI Units SI Units
Serum/Plasma 3-500 U/L 0.05-8.33 μkat/L 1.5-6.0 g/dL 15-60 g/L

CSF N/A N/A N/A N/A
Precision Specification SI Units SI Units
Serum/Plasma ≤ 10% CV ≤ 10% CV ≤ 3% CV ≤ 3% CV

CSF N/A N/A N/A N/A
Reagent Volume
AU400/AU600/AU640 R1 = 100 μL, R2 = 50 μL R1 = 58 μL

AU480/AU680/AU2700/AU5400 R1 = 50 μL, R2 = 25 μL R1 = 46 μL
R1 = 50 μL, R1-2 = 5 μL, R2 = 25 μL (AU680 3-part reagent)
Cartridge Part Number/Size
AU400/AU600/AU640 OSR6007 (4 x 110 tests) OSR6102 (4 x 500 tests)
OSR6107 (4 x 500 tests) OSR6202 (4 x 910 tests)
AU480/AU680/AU2700/AU5400 OSR6007 OSR6102 (4 x 620 tests)
OSR6507 (4 x 1860 tests)†
Liquid or Lyophilized Liquid Liquid
On-Instrument Stability Without P-5P: 30 days 90 days
With P-5P: 7 days
With P-5P: AU680 (3 part-reagent) 30 days
Storage Temperature +2 to +8°C +2 to +25°C
Calibration Frequency Run in MB mode User defined
Compatible Anticoagulants EDTA EDTA
Heparin Heparin
Calibrator Part Number 66300 66300
Control Name Control Serum 1 & 2 Control Serum 1 & 2
Control Part Number ODC0003, ODC0004 ODC0003, ODC0004
Comment(s) †
AU680/AU2700/AU5400 only
4
General Chemistry
Alkaline Phosphatase Alkaline Phosphatase
Chemistry Name
(GSCC) (IFCC)
Chemistry Abbreviation ALP ALP
Measurement Principle GSCC DEA Buffer IFCC AMP Buffer
Reaction Type Rate Rate
Measuring Points 13, 19 (AU400/AU600/AU640) 13, 19 (AU400/AU600/AU640)
16, 27 (AU480/AU680/AU2700/AU5400) 16, 27 (AU480/AU680/AU2700/AU5400)
Serum/Plasma 3 μL (Pediatric: 3 μL) 3 μL (Pediatric: 3 μL)
Urine N/A N/A
CSF N/A N/A
AU2700/AU5400)
Serum/Plasma 1.8 μL (Pediatric: 1.8 μL) 1.8 μL (Pediatric: 1.8 μL)
Urine N/A N/A
CSF N/A N/A
Serum/Plasma Male: Male: Adults: > 17 years: 30-120 U/L Adults > 17 years: 0.5-2 μkat/L
80-300 U/L 1.3-5.0 μkat/L Male children: Male children:
Female: Female: 1–30 days: 75-316 U/L, 1–30 days: 1.25-5.27 μkat/L,
64-300 U/L 1.0-5.0 μkat/L 30 days–1 year: 82-383 U/L 30 days–1 year: 1.37-6.38 μkat/L
Children up to 15 years: Children up to 1–3 years: 104-345 U/L 1–3 years: 1.73-5.75 μkat/L
Up to 640 U/L 15 years: 4–6 years: 93-309 U/L 4–6 years: 1.55-5.15 μkat/L
Up to 10.6 μkat/L 7–9 years: 86-315 U/L 7–9 years: 1.43-5.25 μkat/L
10–12 years: 42-362 U/L 10–12 years: 0.70-6.03 μkat/L
Children 15–17 years: Children 15–17 years: 13–15 years: 74-390 U/L 13–15 years: 1.23-6.50 μkat/L
Up to 480 U/L Up to 8.0 μkat/L 16–18 years: 52-171 U/L 16–18 years: 0.87-2.85 μkat/L
Female children: Female children:
1–30 days: 48-406 U/L, 1–30 days: 0.80-6.77 μkat/L,
30 days–1 year: 124-341 U/L 30 days–1 year: 2.07-5.68 μkat/L
CSF N/A N/A N/A N/A
Serum/Plasma 5-1500 U/L 0.1-25.0 μkat/L 5-1500 U/L 0.1-25.0 μkat/L
CSF N/A N/A N/A N/A
CSF N/A N/A N/A N/A
Reagent Volume
AU400/AU600/AU640 R1 = 60 μL, R2 = 60 μL R1 = 60 μL, R2 = 60 μL
AU480/AU680/AU2700/AU5400 R1 = 36 μL, R2 = 36 μL R1 = 36 μL, R2 = 36 μL
OSR6104 (4 x 485 tests)
OSR6204 (4 x 880 tests)
AU480/AU680/AU2700/AU5400 OSR6103 (4 x 820 tests) OSR6004 (4 x 310 tests)
OSR6104 (4 x 820 tests)
OSR6204 (4 x 1450 tests)
On-Instrument Stability 14 days 14 days
Storage Temperature +2 to +8° C +2 to +8° C
Calibration Frequency Run in MB mode Run in MB mode
Compatible Anticoagulants Heparin Heparin
Comment(s)
5
General Chemistry
Aspartate Aminotransferase
Chemistry Name Amylase (CNP63) Amylase (IFCC-EPS)
(IFCC)
Chemistry Abbreviation AMY AMY AST
Measurement Principle CNPG3 IFCC-EPS IFCC (with/without pyridoxal Phosphate
Activation)
Reaction Type Rate Rate Rate
Primary Wavelength 410 nm 410 nm 340 nm
Measuring Points 5, 10 20, 27 14, 27
Sample Type Serum/Plasma/Urine Serum/Plasma/Urine Serum/Plasma
Serum/Plasma 2 μL 4 μL 10 μL (Pediatric: 10 μL)
Urine 1 μL 1.5 μL N/A
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 1.6 μL 2 μL 5 μL (Pediatric: 5 μL)
Urine 1 μL 1 μL N/A
CSF N/A N/A N/A
Reference Interval SI Units SI Units SI Units
Serum/Plasma 22-80 U/L 0.36-1.33 μkat/L 28-100 U/L 0.46-1.66 μkat/L Male: < 50 U/L Male: < 0.85
μkat/L
Female: Female:
< 35 U/L < 0.60 μkat/L
Newborn: Newborn:
25-75 U/L 0.42-1.25 μkat/L
Infant: 15-60 U/L Infant:
0.25-1.00 μkat/L
Urine 42-321 U/L 0.7-5.35 μkat/L Male: ≤ 490 U/L or Male: N/A N/A
280 U/g creatinine ≤ 8.16 μkat/L
Female: ≤ 450 Female:
U/L or 380 U/g ≤ 7.50 μkat/L
creatinine
CSF N/A N/A N/A N/A N/A N/A
Analytical Range SI Units SI Units SI Units
Serum/Plasma 10-2000 U/L 0.2-33.3 μkat/L 10-1500 U/L 0.2-25.0 μkat/L 3-1000 U/L 0.05-16.7 μkat/L
Urine 5-4800 U/L 0.1-80 μkat/L 10-4800 U/L 0.0-80.0 μkat/L N/A N/A
Precision Specification SI Units SI Units SI Units
Serum/Plasma ≤ 10% CV ≤ 10% CV ≤ 5% CV ≤ 5% CV ≤ 10% CV ≤ 10% CV
Urine ≤ 10% CV ≤ 10% CV ≤ 10% CV ≤ 10% CV N/A N/A
Reagent Volume
AU400/AU600/AU640 Serum/Plasma: R1 = 200 μL Serum/Plasma: R1 = 200 μL, R2 = 50 μL R1 = 50 μL, R2 = 50 μL
Urine: R1 = 150 μL Urine: R1 = 150 μL, R2 = 38 μL
AU480/AU680/AU2700/AU5400 Serum/Plasma R1 = 160 μL R1 = 100 μL, R2 = 25 μL R1 = 25 μL, R2 = 25 μL
Urine: R1 = 150 μL (AU480/AU680/AU2700/AU5400)
R1 = 25 μL, R1-2 = 5 μL, R2 = 25 μL
(AU680 3-part reagent)
AU400/AU600/AU640 OSR6006 (4 x 50 tests) OSR6182 (4 x 200 tests) OSR6009 (4 x 105 tests)
OSR6209 (4 x 1000 tests)
AU480/AU680/ OSR6006 (4 x 60 tests) OSR6182 (4 x 400 tests) OSR6009
AU2700/AU5400 OSR6106 (4 x 240 tests) OSR6109 (4 x 980 tests)
OSR6209 (4 x 1960 tests)
OSR6509 (4 x 3700 tests)†
Liquid or Lyophilized Liquid Liquid Liquid
On-Instrument Stability 30 days 90 days Without P-5P: 30 days
With P-5P: 7 days
With P-5P: AU680 (3 part-reagent) 30
days
Storage Temperature +2 to +8°C +2 to +8°C +2 to +8°C
Calibration Frequency Run in MB mode Run in MB mode Run in MB mode
Compatible Anticoagulants Heparin Heparin Heparin
Calibrator Part Number Serum/Plasma: 66300 Serum/Plasma: 66300 66300
Urine: ODC0025 Urine: ODC0025
Control Name Serum/Plasma: Control Serum 1 & 2 Serum/Plasma: Control Serum 1 & 2 Control Serum 1 & 2
Urine: Bio-Rad Liquichek* Urine Urine: Bio-Rad Liquichek* Urine
Chemistry Controls Chemistry Controls
Control Part Number Serum/Plasma: ODC0003, ODC0004 Serum/Plasma: ODC0003, ODC0004 ODC0003, ODC0004
Urine: 397, 398 Urine: 397, 398
Comment(s) †
6
General Chemistry
Chemistry Name Bicarbonate Calcium Arsenazo Calcium oCPC
Chemistry Abbreviation CO2 CALA CA

Measurement Principle Enzymatic PEP-MD Arsenazo III o-Cresolphthalein Complexone
Reaction Type Fixed End End
Measuring Points 1, 9 0, 10 0, 27 / 0, 10
Sample Type Serum/Plasma Serum/Plasma/Urine Serum/Plasma/Urine
Serum/Plasma 3 μL (Pediatric: 3 μL) 3.5 μL (Pediatric: 3.5 μL) 5 μL (Pediatric: 5 μL)
Urine N/A 2 μL 2 μL
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 2.5 μL (Pediatric: 2.5 μL ) 2.5 μL (Pediatric: 2.5 μL) 3.7 μL (Pediatric: 3.7 μL)
Urine N/A 2 μL 1.5 μL
CSF N/A N/A N/A
Serum/Plasma N/A Adults: Adults: Adults: Adults: Adults:
21-31 mmol/L 8.8-10.6 mg/dL 2.20-2.65 mmol/L 8.8-10.6 mg/dL 2.20-2.65 mmol/L
Newborn: Children 0–10 days: Children 0–10 Children 0–10 days: Children 0–10 days:
17-24 mmol/L 7.6-10.4 mg/dL days: 1.90-2.60 7.6-10.4 mg/dL 1.90-2.60 mmol/L
Infant: mmol/L Children 2–12 years: Children 2–12 years:
19-24 mmol/L Children 2–12 years: Children 2–12 8.8-10.8 mg/dL 2.20-2.70 mmol/L
2 months–2 years: 8.8-10.8 mg/dL years: 2.20-2.70
16-24 mmol/L mmol/L
Urine N/A N/A Female: Female: Female: Female:
< 250 mg/24 hrs < 6.2mmol/24 hrs < 250 mg/24 hrs < 6.2 mmol/24 hrs
Male: Male: Male: Male:
< 300 mg/24 hrs < 7.5 mmol/24 hrs < 300 mg/24 hrs < 7.5 mmol/24 hrs
Serum/Plasma N/A 2-45 mmol/L 4-20 mg/dL 1-5 mmol/L 0-18 mg/dL 0-4.5 mmol/L
Urine N/A N/A 0-40 mg/dL 0-10 mmol/L 0-40 mg/dL 0-10 mmol/L
Serum/Plasma N/A ≤ 7% CV or SD ≤ ≤ 1.25% CV @ > 14 ≤ 1.25% CV @ > ≤ 5% CV ≤ 5% CV
1.5 mmol/L mg/dL, 3.5 mmol/L,
SD ≤ 0.175 mg/dL SD ≤ 0.044 mmol/L
@ ≤ 14 mg/dL @ ≤ 3.5 mmol/L
Urine N/A N/A ≤ 2.0% or SD ≤ ≤ 2.0% or SD ≤ ≤ 5% CV ≤ 5% CV
0.28 mg/dL 0.07 mmol/L
Reagent Volume
AU400/AU600/AU640 R1 = 50 μL Serum: R1 = 29 μL Serum: R1 = 60 μL, R2 = 60 μL
AU480/AU680/AU2700/AU5400 R1 = 42 μL Serum: R1 = 21 μL Serum: R1 = 45 μL, R2 = 45 μL
OSR6290 (4 x 1000 tests) OSR61117 (4 x 930 tests) OSR6213 (4 x 815 tests)
AU480/AU680/ OSR6190 (4 x 580 tests) OSR60117 (4 x 700 tests) OSR6113 (4 x 590 tests)
AU2700/AU5400 OSR6290 (4 x 1160 tests) OSR61117 (4 x 1313 tests) OSR6213 (4 x 1080 tests)
On-Instrument Stability 7 days 90 days 30 days
Calibration Frequency Daily User defined Daily
Calibrator Part Number ODC0019 Serum/Plasma: 66300 Serum/Plasma: 66300
Control Name N/A Serum/Plasma: Control Serum 1 & 2 Serum/Plasma: Control Serum 1 & 2
Control Part Number N/A Serum: ODC0003, ODC0004 Serum: ODC0003, ODC0004
Urine: 397, 398 Urine: 397, 398
Comment(s)
7
General Chemistry
Chemistry Name Cholesterol Cholesterol† Creatine Kinase
Chemistry Abbreviation CHOL CHOL CK

Measurement Principle CHO-POD CHOD-POD IFCC NAC activated
Reaction Type End End Rate
Measuring Points 0, 27 0, 27 / 0, 10 21, 27
Sample Type Serum/Plasma Serum/Plasma Serum/Plasma
Serum/Plasma 3 μL 2 μL 3 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 1.6 μL 1.6 μL 2.5 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma Desirable: Desirable: Desirable: Desirable: Male: Male:
< 200 mg/dL < 5.2 mmol/L < 200 mg/dL < 5.2 mmol/L ≤ 171 U/L ≤ 2.85 μkat/L
Borderline High: Borderline High: Borderline High: Borderline High: Female: Female:
200-239 mg/dL 5.2-6.2 mmol/L 200-239 mg/dL 5.2-6.2 mmol/L ≤ 145 U/L ≤ 2.42 μkat/L
High ≥ 240 mg/dL High: ≥ 6.2 High ≥ 240 mg/dL High: ≥ 6.2
mmol/L mmol/L
Urine N/A N/A N/A N/A N/A N/A
Serum/Plasma 20-700 mg/dL 0.5-18 mmol/L 12-700 mg/dL 0.3-18.0 mmol/L 10-2000 U/L 0.17-33.33 μkat/L
Reagent Volume
AU400/AU600/AU640 R1 = 45 μL R1 = 120 μL, R2 = 30 μL R1 = 120 μL, R2 = 30 μL1
AU480/AU680/AU2700/AU5400 R1 = 24 μL R1 = 96 μL, R2 = 24 μL R1 = 100 μL, R2 = 25 μL1
OSR6516 (4 x 3975 tests)†
Calibration Frequency User defined 30 days Run in MB mode
Compatible Anticoagulants EDTA EDTA Heparin
Heparin Heparin
Calibrator Part Number 66300 66300 66300
Control Name Control Serum 1 & 2 Control Serum 1 & 2 Control Serum 1 & 2
Control Part Number ODC0003, ODC0004 ODC0003, ODC0004 ODC0003, ODC0004
Comment(s) †
AU680/AU2700/AU5400 only Applicable to Austria and Korea
†
Transfer R1-2 into R1-1 and mix by
1
markets only gentle inversion
8
General Chemistry
Chemistry Name Creatinine Creatinine (Enzymatic)
Chemistry Abbreviation CRE CREZ

Measurement Principle Modified Jaffe, Kinetic Enzymatic
Reaction Type Fixed End
Measuring Points 13, 24 0, 27 / 0, 10
Sample Type Serum/Plasma/Urine Serum/Plasma/Urine
AU640)
Serum/Plasma 20 μL (Pediatric: 20 μL) 7 μL
Urine 2 μL 1 μL
CSF N/A N/A
AU2700/AU5400)
Serum/Plasma 8 μL (Pediatric: 8 μL) 5.6 μL
Urine 1.6 μL 1 μL
CSF N/A N/A
Serum/Plasma Method A:1 Method B:2 Method A:1 Method B:2 Male: Male:
Male: 0.67-1.17 mg/dL Male < 50 years: Male: 59-104 μmol/L Male < 50 years: 0.72-1.18 mg/dL 64-104 μmol/L
Female: 0.51-0.95 mg/dL 0.84-1.25 mg/dL Female: 45-84 μmol/L 74-110 μmol/L
Neonate: 0.31-0.98 mg/dL Male > 50 years: Neonate: 27-87 μmol/L Male > 50 years: Female: Female:
Infant: 0.16-0.39 mg/dL 0.81-1.44 mg/dL Infant: 14-34 μmol/L 72-127 μmol/L 0.55-1.02 mg/dL 49-90 μmol/L
Child: 0.26-0.77 mg/dL Female: 0.66-1.09 mg/dL Child: 23-68 μmol/L Female: 58-96 μmol/L
Neonate: 0.5-1.2 mg/dL Neonate: 45-105 μmol/L
Infant: 0.4-0.7 mg/dL Infant: 35-62 μmol/L
Child: 0.5-1.2 mg/dL Child: 45-105 μmol/L
Urine Method A/B: Method A/B: Male: 14-26 mg/ Male: 124-230
Male: 14-26 mg/kg/24 hrs Male: 124-230 μmol/Kg/24 hrs kg/24 hrs μmol/kg/24 hrs
Female: 11-20 mg/kg/24 hrs Female: 97-177 μmol/Kg/24 hrs Female: 11-20 mg/ Female: 97-177
kg/24 hrs μmol/kg/24 hrs
CSF N/A N/A N/A N/A
Serum/Plasma Method A: 0.06-25.0 mg/dL Method A: 5-2200 μmol/L 0.05-50 mg/dL 4.4-4420 μmol/L
Method B: 0.2-25 mg/dL Method B: 18-2200 μmol/L
Urine 1-400 mg/dL 88-35360 μmol/L 1-500 mg/dL 88-44200
μmol/L
CSF N/A N/A N/A N/A
Urine ≤ 5% CV ≤ 5% CV
CSF N/A N/A N/A N/A
Reagent Volume
AU400/AU600/AU640 Serum/Plasma: R1 = 120 μL, R2 = 120 μL Serum/Plasma:
Urine: R1 = 58 μL, R2 = 58 μL R1 = 150 μL, R2 = 50 μL
Urine: R1 = 150 μL, R2 = 50 μL
AU480/AU680/AU2700/ Serum: R1 = 48 μL, R2 = 48 μL Serum/Plasma:
AU5400 Urine: R1 = 47 μL, R2 = 47 μL R1 = 120 μL, R2 = 40 μL
Urine: R1 = 150 μL, R2 = 50 μL
AU480/AU680/ OSR6178 (4 x 990 tests) OSR61204 (4 x 360 tests)
AU2700/AU5400 OSR6578 (4 x 1870 tests)†
Calibration Frequency Daily Serum/Plasma: 14 days
Urine: 30 days
Compatible Anticoagulants EDTA Heparin
Heparin
Calibrator Part Number Serum/Plasma: 66300 Serum/Plasma: 66300
Control Name Serum/Plasma: Control Serum Level 1 & 2 Serum/Plasma: Control Serum 1 & 2
Urine: Bio-Rad Liquichek* Urine Chemistry Controls Urine: Bio-Rad Liquichek* Urine
Chemistry Controls
Control Part Number Serum/Plasma: ODC0003, ODC0004 Serum/Plasma: ODC0003, ODC0004
Urine: 397, 398 Urine: 397, 398
Comment(s) 1
Method A: Kinetic Jaffe (compensated method) traceable to the IDMS reference method
2
Method B: Kinetic Jaffe uncompensated † AU680/AU2700/AU5400 only
9
General Chemistry
Chemistry Name Direct Bilirubin Gamma-Glutamyltransferase
Chemistry Abbreviation DBIL1 GGT

Measurement Principle DPD IFCC
Reaction Type End, Sample Blank (2 cuvettes) Rate
Measuring Points 0, 2 14, 23 (AU400/AU600/AU640)
16, 23 (AU480/AU680/AU2700/AU5400)
Serum/Plasma 3 μL (Pediatric: 3.5 μL) 5 μL (Pediatric: 5 μL)
Urine N/A N/A
CSF N/A N/A
AU2700/AU5400)
Serum/Plasma 2.5 μL (Pediatric: 2.7 μL) 4 μL (Pediatric: 4 μL)
Urine N/A N/A
CSF N/A N/A
Serum/Plasma Adults and Adults and Male: < 55 U/L Male: < 0.92 μkat/L
children: < 0.2 children: < 3.4 Female: < 38 U/L Female: < 0.63 μkat/L
mg/dL μmol/L
Male children Male children
1–182 days: 12-122 U/L 1–182 days: 0.2-2.03 μkat/L
Female children Female children
13–18 years: 4-24 U/L 13–18 years : 0.07-0.4 μkat/L
CSF N/A N/A N/A N/A
Serum/Plasma 0-10 mg/dL 0-171 μmol/L 5-1200 U/L 0.08-20 μkat/L
CSF N/A N/A N/A N/A
Serum/Plasma ≤ 5% CV or ≤ 5% CV or ≤ 10% CV ≤ 10% CV
SD ≤ 0.07 mg/dL SD ≤ 1.20 μmol/L
CSF N/A N/A N/A N/A
Reagent Volume
AU400/AU600/AU640 R1 = 30 μL R1 = 80 μL, R2 = 80 μL
AU480/AU680/AU2700/AU5400 R1 = 25 μL R1 = 64 μL, R2 = 64 μL
OSR6520 (4 x 1485 tests)†
Calibration Frequency 21 days Run in MB mode
Compatible Anticoagulants Heparin EDTA
Heparin
Control Part Number ODC0003 , ODC0004 ODC0003, ODC0004
Comment(s) 1
Both a color test DBIL-C and blank test †
DBIL-B need to be run
10
General Chemistry
Chemistry Name Glucose Glucose – STAT HDL Cholesterol
Chemistry Abbreviation GLU GLU-S HDL-C

Measurement Principle Hexokinase Hexokinase Enzymatic Immunoinhibition
Reaction Type End End End
Measuring Points 0 , 27 / 0, 10 0, 10 0, 27 / 0, 10
Sample Type Serum/Plasma/Urine/CSF/Hemolysate Serum/Plasma Serum/Plasma
Serum/Plasma 2 μL (Pediatric: 2 μL) 2 μL 2 μL
Urine 2 μL N/A N/A
CSF 2 μL N/A N/A
Hemolysate 20 μL N/A N/A
AU2700/AU5400)
Serum/Plasma 1.6 μL (Pediatric: 1.6 μL) 1.6 μL 1.6 μL
Urine 1.2 μL N/A N/A
CSF 1.6 μL N/A N/A
Hemolysate 16 μL N/A N/A
Serum/Plasma Adults: Adults: 74-106 mg/dL 4.1-5.9 mmol/L Low HDL: Low HDL:
74-106 mg/dL 4.1-5.9 mmol/L < 40 mg/dL < 1.03 mmol/L
Children: Children: High HDL: High HDL:
60-100 mg/dL 3.3- 5.6 mmol/L ≥ 60 mg/dL ≥ 1.55 mmol/L
Urine 1-15 mg/dL 0.1-0.8 mmol/L N/A N/A N/A N/A
CSF 40-70 mg/dL 2.2-3.9 mmol/L N/A N/A N/A N/A
Hemolysate 60-100 mg/dL 3.3-5.5 mmol/L N/A N/A N/A N/A
Serum/Plasma 10-800 mg/dL 0.6-45 mmol/L 10-800 mg/dL 0.6-45 mmol/L 2-180 mg/dL 0.05-4.65 mmol/L
Urine 1-800 mg/dL 0-45 mmol/L N/A N/A N/A N/A
CSF 10-800 mg/dL 0.6-45 mmol/L N/A N/A N/A N/A
Hemolysate 10-800 mg/dL 0.6-45 mmol/L N/A N/A N/A N/A
Urine ≤ 3% CV ≤ 3% CV N/A N/A N/A N/A
CSF ≤ 3% CV ≤ 3% CV N/A N/A N/A N/A
Hemolysate ≤ 5% CV ≤ 5% CV N/A N/A N/A N/A
Reagent Volume
AU400/AU600/AU640 R1 = 50 μL, R2 = 25 μL R1 = 75 μL R1 = 180 μL, R2 = 60 μL
AU480/AU680/AU2700/AU5400 Serum: R1 = 40 μL, R2 = 20 μL R1 = 60 μL R1 = 144 μL, R2 = 48 μL
Urine: R1 = 30 μL, R2 = 15 μL
CSF: R1 = 40 μL, R2 = 20 μL
Hemolysate: R1 = 40 μL, R2 = 20 μL
OSR6521 (4 x 2265 tests)† OSR6587 (4 x 695 tests)†
Calibration Frequency 30 days 30 days 30 days
Compatible Anticoagulants EDTA EDTA Heparin
Heparin Heparin
Calibrator Part Number Serum/Plasma/CSF/Hemolysate: 66300 ODC0011
66300
Urine: ODC0025
Control Name Serum/Plasma/Hemolysate: Control Control Serum 1 & 2 HDL/LDL-Cholesterol Control Serum
Serum 1 & 2 Levels 1 & 2
Urine: Bio-Rad Liquichek* Urine
Chemistry Controls
CSF: N/A
Control Part Number Serum/Plasma/Hemolysate: ODC0003, ODC0003, ODC0004 ODC0005
ODC0004
Urine: 397, 398
CSF: N/A
Comment(s) †
AU680/AU2700/AU5400 only †
11
General Chemistry
Chemistry Name Hydroxybutyrate Dehydrogenase Iron LDL Cholesterol
Chemistry Abbreviation HBDH IRON LDL-C

Measurement Principle GSCC TPTZ Enzymatic Selective Protection
Reaction Type Rate End End
Measuring Points 12, 27 (AU400/AU600/AU640) 0, 12 / 0, 10 0, 27 / 0, 10
13, 27 (AU480/AU680/AU2700/
AU5400)
Serum/Plasma 3 μL 20 μL (Pediatric: 20 μL) 2 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
Sample Size (AU480/AU680/ 2.5 μL
AU2700/AU5400)
Serum/Plasma N/A 12 μL (Pediatric: 12 μL) 1.6 μL
Urine N/A N/A N/A
CSF N/A N/A
Serum/Plasma Adults: Adults: Male: Male: Optimal: Optimal:
90-180 U/L 1.5-3 μkat/L 70-180 μg/dL 12.5-32.2 μmol/L < 2.6 mmol/L < 100 mg/dL
Female: Female: Near Optimal/ Near Optimal/
60-180 μg/dL 10.7-32.2 μmol/L Above Optimal: Above Optimal:
Newborn: Newborn: 17.90- 2.6-3.3 mmol/L 100-129 mg/dL
100-250 μg/dL 44.8 μmol/L Borderline High: Borderline High:
Infant: Infant: 3.4-4.1 mmol/L 130-159 mg/dL
40-100 μg/dL 7.2-17.9 μmol/L High: High:
Child: Child: 4.1-4.9 mmol/L 160-189 mg/dL
50-120 μg/dL 9.0-21.5 μmol/L Very High: Very High:
≥ 4.9 mmol/L ≥ 190 mg/dL
Analytical Range SI Units SI Units 0.26-10.3 mmol/L 10-400 mg/dL
Serum/Plasma 40-1000 U/L 0.67-16.67 μkat/L 10-1000 μg/dL 2-179 μmol/L N/A N/A
CSF N/A N/A N/A N/A SI Units
Precision Specification SI Units SI Units N/A N/A
Serum/Plasma ≤ 10% CV ≤ 10% CV ≤ 5% CV ≤ 5% CV N/A N/A
CSF N/A N/A N/A N/A
Reagent Volume
AU400/AU600/AU640 R1 = 75 μL, R2 = 75 μL R1 = 50 μL, R2 = 50 μL R1 = 180 μL, R2 = 60 μL
AU480/AU680/AU2700/AU5400 R1 = 63 μL, R2 = 63 μL R1 = 30 μL, R2 = 30 μL R1 = 144 μL, R2 = 48 μL
Calibration Frequency Run in MB mode User defined 30 days
Calibrator Part Number 66300 66300 ODC0012
Control Name Control Serum 1 & 2 Control Serum 1 & 2 HDL/LDL-Cholesterol Control Serum
Levels 1 & 2
Control Part Number ODC0003, ODC0004 ODC0003, ODC0004 ODC0005
Comment(s)
12
General Chemistry
Lactate Dehydrogenase Lactate Dehydrogenase
Chemistry Name Lipase
(IFCC) (SCE)
Chemistry Abbreviation LDH LDH26 LIP
Measurement Principle LDH (L-P) IFCC Lactate-Pyruvate (NAD); SCE Colorimetric
Reaction Type Rate Rate Rate
Measuring Points 14,23 (AU400/AU640) 12, 27 (AU400/AU600/AU640) 17, 27
15, 23 (AU480/AU680/ 13, 27 (AU480/AU680/
AU2700/AU5400) AU2700/AU5400)
Serum/Plasma 3 μL (Pediatric: 3 μL) 3 μL (Pediatric: 3 μL) 2 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 2.3 μL (Pediatric: 2.3 μL) 1.8 μL (Pediatric: 1.8 μL) 1.6 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma Female: Female: Adults: Adults: Adults: Adults:
< 247 U/L < 4.12 μkat/L 208- 378 U/L 3.47-6.30 μkat/L < 67 U/L < 1.12 μkat/L
Male: Male: Children: Children:
< 248 U/L < 4.13 μkat/L 1 day: < 1327 U/L 1 day: < 22.1 μkat/L
Children 0–4 days: Children 0–4 2–5 days: 2–5 days:
290−-775 U/L days: 4.83-12.92 < 1732 U/L < 28.9 μkat/L
μkat/L 6 days–6 months: 6 days–6 months:
4–10 days: 545−- 4–10 days: < 975 U/L < 16.3 μkat/L
2000 U/L 9.1-33.3 μkat/L 4–6 years: 4–6 years:
10 days–24 months: 10 days–24 < 615 U/L < 10.3 μkat/L
180−-430 U/L months:
3.0-7.2 μkat/L
24 months–12 24 months–
years: 110−-295 U/L 12 years:
1.83-4.92 μkat/L
Serum/Plasma 25-1200 U/L 0.4-20.0 μkat/L 50-3000 U/L 0.8-50.0 μkat/L 3-600 U/L 0.05-10 μkat/L
Reagent Volume
AU400/AU600/AU640 R1 = 80 μL, R2 = 40 μL R1 = 100 μL, R2 = 50 μL R1 = 180 μL, R2 = 60 μL1
AU480/AU680/AU2700/AU5400 R1 = 62 μL, R2 = 31 μL R1 = 60 μL, R2 = 30 μL R1 = 144 μL, R2 = 48 μL1
OSR6230 (4 x 165 tests)
AU2700/AU5400 OSR6230 (4 x 195 tests)
Liquid or Lyophilized Liquid Liquid Lyophilized/Liquid
Calibration Frequency Run in MB mode Run in MB mode 7 days
Compatible Anticoagulants Heparin Heparin EDTA
Heparin
Calibrator Part Number 66300 66300 Included
Control Name Control Serum 1 & 2 Control Serum 1 & 2 Control Serum 1 & 2
Control Part Number ODC0003, ODC0004 ODC0003, ODC0004 ODC0003, ODC0004
Comment(s) 1
Dissolve contents of 1 vial of R1 with
the contents of 1 vial of R1 buffer
13
General Chemistry
Phosphorus
Chemistry Name Magnesium Total Bilirubin
(Inorganic)
Chemistry Abbreviation MG PHOS TBIL1
Measurement Principle Xylidyl Blue, Colourimetric, Tris-Buffer Phosphomolybdate Complex DPD
Reaction Type End End End, Sample Blank (2 cuvette)
Measuring Points 0, 27 (AU400/AU600/AU640) 0, 27 / 0, 10 0, 10
0, 10 (AU480/AU680/
AU2700/AU5400)
Sample Type Serum/Plasma/Urine Serum/Plasma/Urine Serum/Plasma
Serum/Plasma 2 μL 3 μL 6 μL (Pediatric: 6 μL)
Urine 1 μL 2 μL of a 1/10 N/A
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 1.6 μL 2.5 μL 5 μL (Pediatric: 5 μL)
Urine 1 μL 1.7 μL of a 1/10 N/A
CSF N/A N/A N/A
Serum/Plasma Male: Male: 2.5-4.5 mg/dL 0.81-1.45 mmol/L Adults: Adults:
1.8-2.6 mg/dL 0.73-1.06 mmol/L 0.3-1.2 mg/dL 5-21 μmol/L
Female: Female: Children 0–1 days: Children 0–1
1.9-2.5 mg/dL 0.77-1.03 mmol/L 1.4-8.7 mg/dL days: 24–149
1–2 days: μmol/L
3.4-11.5 mg/dL 1–2 days:
3–5 days: 58-197 μmol/L
1.5-12.0 mg/dL 3–5 days:
26-205 μmol/L
Urine 73-122 mg/24 hrs 3-5 mmol/24 hrs 0.4-1.3 g/24 hrs 12.9-42 mmol N/A N/A
/24 hrs
Serum/Plasma 0.5-8.0 mg/dL 0.2-3.3 mmol/L 1-20 mg/dL 0.32-6.40 0-30 mg/dL 0-513 μmol/L
mmol/L
Urine 0.5-22.5 mg/dL 0.2-9.25 mmol/L 0-350 mg/dL 0-113 mmol/L N/A N/A
Serum/Plasma ≤ 5% CV ≤ 5% CV ≤ 5% CV ≤ 5% CV ≤ 5% CV or SD ≤ ≤ 5% CV or SD ≤
0.10 mg/dL 1.71 μmol/L
Urine ≤ 5% CV or ≤ 5% CV or N/A N/A
SD ≤ 2.48 mg/dL SD ≤ 0.8 mmol/L
at ≤ 46.5 mg/dL at ≤ 15 mmol/L
Reagent Volume
AU400/AU600/AU640 R1 = 200 μL R1 = 30 μL, R2 = 30 μL R1 = 30 μL
AU480/AU680/AU2700/AU5400 Serum: R1 = 160 μL R1 = 25 μL, R2 = 25 μL R1 = 25 μL
Urine: R1 = 200 μL
Calibration Frequency 7 days 30 days User defined
Compatible Anticoagulants Heparin Heparin EDTA
Heparin
Calibrator Part Number Serum/Plasma: 66300 Serum/Plasma: 66300 66300
Control Name Serum/Plasma: Control Serum 1 & 2 Serum/Plasma: Control Serum 1 & 2 Control Serum 1 & 2
Control Part Number Serum/Plasma: ODC0003, ODC0004 Serum/Plasma: ODC0003, ODC0004 ODC0003, ODC0004
Urine: 397, 398 Urine: 397, 398
Comment(s) Both a color test TBIL-C and blank test
1
TBIL-B need to be run
14
General Chemistry
Chemistry Name Total Protein Triglyceride
Chemistry Abbreviation TP TRIG

Measurement Principle Biuret GPO-POD
Reaction Type END END
Measuring Points 0, 27 / 0, 10 0, 27 / 0, 10
Serum/Plasma 6.0 μL 2 μL (Pediatric: 2 μL)
Urine N/A N/A
CSF N/A N/A
AU2700/AU5400)
Serum/Plasma 5 μL 1.6 μL (Pediatric: 1.6 μL)
Urine N/A N/A
CSF N/A N/A
Serum/Plasma 6.6-8.3 g/dL 66-83 g/L Normal: Normal:
< 150 mg/dL < 1.7 mmol/L
Borderline High: Borderline High:
150-199 mg/dL 1.70-2.25 mmol/L
High: High: 2.26-5.64
200-499 mg/dL mmol/L
Very High: Very High:
≥ 500 mg/dL ≥ 5.65 mmol/L
CSF N/A N/A N/A N/A
Serum/Plasma 3-12 g/dL 30-120 g/L 10-1000 mg/dL 0.1-11.3 mmol/L
CSF N/A N/A N/A N/A
CSF N/A N/A N/A N/A
Reagent Volume
Calibration Frequency User defined 30 days
Compatible Anticoagulants EDTA EDTA
Heparin Heparin
Control Name Control Serum 1& 2 Control Serum 1 & 2
Comment(s)
15
General Chemistry
Chemistry Name Unsaturated Iron Binding Capacity Unsaturated Iron Binding Capacity
Chemistry Abbreviation UIBC UIBC

Measurement Principle Nitroso-PSAP Nitroso – PSAP
Reaction Type End End
Measuring Points 0, 27 / 0, 10 0 , 27 / 0, 10
Serum/Plasma 10 μL 10 μL
Urine N/A N/A
CSF N/A N/A
AU2700/AU5400)
Serum/Plasma 8 μL 8 μL
Urine N/A N/A
CSF N/A N/A
Serum/Plasma 155-355 μg/dL 27.8-63.6 μmol/L 155-300 μg/dL 27.8-53.7 μmol/L

CSF N/A N/A N/A N/A
Serum/Plasma 55-550 μg/dL 10-100 μmol/L 55-450 μg/dL 9.8-80.6 μmol/L

CSF N/A N/A N/A N/A

CSF N/A N/A N/A N/A
Reagent Volume
AU400/AU600/AU640 R1 = 150 μL, R2 = 30 μL1 R1 = 150 μL, R2 = 30 μL1

AU480/AU680/AU2700/AU5400 R1 = 120 μL, R2 = 24 μL1 R1 = 120 μL, R2 = 24 μL1

AU2700/AU5400
Calibration Frequency 14 days 14 days
Compatible Anticoagulants Heparin Heparin
Comment(s) 1
Transfer R1a into R1 and R2a into R2 1
Transfer R1a into R1 and R2a into R2
16
General Chemistry
Chemistry Name Urea Urea - STAT Uric Acid
Chemistry Abbreviation UREA UREAS UA

Measurement Principle GLDH, Kinetic Assay GLDH, Kinetic Assay Uricase PAP
Reaction Type Rate Rate END
Sample Type Serum/Urine Serum/Plasma Serum/Plasma/Urine
Serum/Plasma 2.5 μL (Pediatric: 2.5 μL) 2.5 μL 7 μL
Urine 2 μL N/A 1.5 μL
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 2 μL (Pediatric: 2 μL) 2 μL 5.6 μL
Urine 1.6 μL N/A 1.2 μL
CSF N/A N/A N/A
Serum/Plasma Adults: Adults: 17-43 mg/dL 2.8-7.2 mmol/L Male: Male:
17-43 mg/dL 2.8-7.2 mmol/L 3.5-7.2 mg/dL 208.3-428.4 μmol/L
Newborn: Newborn: Female: Female:
8.4-25.8 mg/dL 1.4-4.3 mmol/L 2.6-6.0 mg/dL 154.7-357.0 μmol/L
Infant/Child: Infant/Child:
10.8-38.4 mg/dL 1.8-6.4 mmol/L
Urine 15000-34200 250-570 N/A N/A 250-750 mg/ 1488-4463 μmol/
mg/24 hrs mmol/24 hrs 24 hrs 24 hrs
Serum/Plasma 5-300 mg/dL 0.8-50 mmol/L 5-300 mg/dL 0.8-50 mmol/L 1.5-30 mg/dL 89-1785 μmol/L
Urine 60-4500 mg/dL 10-750 mmol/L N/A N/A 2-400 mg/dL 119-23,800 μmol/L
Urine ≤ 10% CV ≤ 10% CV N/A N/A ≤ 5% CV ≤ 5% CV
Reagent Volume
AU400/AU600/AU640 R1 = 50 μL, R2 = 50 μL R1 = 100 μL R1 = 60 μL, R2 = 25 μL
AU480/AU680/AU2700/AU5400 R1 = 40 μL, R2 = 40 μL R1 = 80 μL R1 = 48 μL, R2 = 20 μL
OSR6234 (4 x 960 tests) OSR6541 (4 x 1000 tests) OSR6198 (4 x 500 tests)
OSR6298 (4 x 705 tests)
AU2700/AU5400 OSR6234 (4 x 1300 tests) OSR6541 (4 x 1200 tests)† OSR6198 (4 x 625 tests)
OSR6534 (4 x 2285 tests)† OSR6298 (4 x 880 tests)
Calibration Frequency User defined User defined 30 days
Compatible Anticoagulants EDTA EDTA EDTA
Lithium Heparin Lithium Heparin Heparin
Calibrator Part Number Serum/Plasma: 66300 66300 Serum/Plasma: 66300
Control Name Serum: Control Serum 1 & 2 Control Serum 1 & 2 Serum/Plasma: Control Serum 1 & 2
Control Part Number Serum: ODC0003, ODC0004 ODC0003, ODC0004 Serum/Plasma: ODC0003/ODC0004
Urine: 397, 398 Urine: 397, 398
Comment(s) †
AU680/AU2700/AU5400 only †
17
General Chemistry
Chemistry Name Urinary/CSF Protein
Chemistry Abbreviation UCSFP

Measurement Principle Pyrogallol Red Molybdate
Reaction Type End
Primary Wavelength 600 nm
Measuring Points 0, 10
Sample Type Urine/CSF
Serum/Plasma N/A
Urine 2 μL
CSF 2 μL
AU2700/AU5400)
Serum/Plasma N/A
Urine 1.6 μL
CSF 1.6 μL
Reference Interval SI Units
Serum/Plasma N/A N/A

Urine 50-80 mg/ 0.05-0.08 g/
24 hrs at rest 24 hrs at rest
CSF Adults: Adults:
15-45 mg/dL 0.15-0.45 g/L
Analytical Range SI Units

Urine 1-200 mg/dL 0.01-2.00 g/L
CSF 1-200 mg/dL 0.01-2.00 g/L
Precision Specification SI Units

Urine ≤ 10% CV ≤ 10% CV
CSF ≤ 10% CV ≤ 10% CV
Reagent Volume
AU400/AU600/AU640 R1 = 190 μL
AU480/AU680/AU2700/AU5400 R1 = 152 μL
AU400/AU600/AU640 OSR6170 (4 x 100 tests)

AU480/AU680/ OSR6170 (4 x 125 tests)
AU2700/AU5400
Liquid or Lyophilized Liquid
On-Instrument Stability 90 days
Storage Temperature +2 to +8°C
Calibration Frequency User defined
Compatible Anticoagulants N/A
Calibrator Part Number Urine/CSF: Included in kit
Control Name N/A
Control Part Number N/A
Comment(s)
18
Proteins/Serology
Chemistry Name Alpha-1-Acidglycoprotein Alpha-1-Antitrypsin Anti-Streptolysin O
Chemistry Abbreviation AAG AAT ASO

Measurement Principle Immunoturbidimetric Immunoturbidimetric Latex Particle Immunoturbidimetric
Reaction Type End End Fixed
Measuring Points 0, 27 / 0, 10 0, 27 / 0, 10 11, 16
Sample Type Serum/Plasma Serum/Plasma Serum
Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma 50-120 mg/dL 0.5-1.2 g/L 90-200 mg/dL 0.9-2.0 g/L N/A Adults:
≤200 IU/mL
Children:
≤150 IU/mL
Serum/Plasma 20-200 mg/dL 0.2-2.0 g/L 30-500 mg/dL 0.3-5.0 g/L N/A 100-1000 IU/mL
Serum/Plasma ≤ 10% CV ≤ 10% CV ≤ 5% CV ≤ 5% CV N/A ≤ 10% CV
Reagent Volume
AU2700/AU5400
Calibration Frequency User defined User defined User defined
Compatible Anticoagulants Heparin Heparin N/A
Calibrator Part Number ODR3023 ODR3023 ODR3021
ODR300372
Control Name ITA Control Serum 1, 2 & 3 ITA Control Serum 1, 2 & 3 ITA Control Serum 1, 2 & 3
Control Part Number ODC0014, ODC0015, ODC0016 ODC0014, ODC0015, ODC0016 ODC0014, ODC0015, ODC0016
Comment(s) Gently invert R2 5-10 times before
1
placing on instrument
2
For Mastercurve enabled systems only
19
Proteins/Serology
Chemistry Name Apolipoprotein A1 Apolipoprotein B Beta-2 Microglobulin
Chemistry Abbreviation APO A1 APO B B2M

Measurement Principle Immunoturbidimetric Immunoturbidimetric Latex Particle Immunoturbidimetric
Reaction Type End End Fixed
Measuring Points 0, 27 / 0, 10 0, 27 / 0, 10 12, 21
Sample Type Serum Serum Serum/ Plasma
Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma Male: Male: Male: Male: < 60 years: < 60 years:

105-175 mg/dL 1.05-1.75 g/L 60-140 mg/dL 0.60-1.40 g/L 0.08 -0.24 mg/dL 0.8-2.4 mg/L
Female: Female: Female: Female: > 60 years: > 60 years:
105-205 mg/dL 1.05-2.05 g/L 55- 130 mg/dL 0.55-1.30 g/L ≤ 0.3 mg/dL ≤ 3.0 mg/L
Serum/Plasma 40-250 mg/dL 0.4-2.5 g/L 40-200 mg/dL 0.4-2.0 g/L 0.05-1.6 mg/dL 0.5-16.0 mg/L

Reagent Volume

AU2700/AU5400
Compatible Anticoagulants N/A N/A EDTA
Heparin
Calibrator Part Number ODR3022 (5-point calibration) ODR3022 (5-point calibration) ODR3023
ODR3005 (3-point Calibration) ODR3005 (3-point calibration)
Control Name Control Serum 1 & 2 Control Serum 1 & 2 ITA Control Serum 1, 2 & 3
Control Part Number ODC0003, ODC0004 ODC0003, ODC0004 ODC0014, ODC0015, ODC0016
Comment(s)
20
Proteins/Serology
Chemistry Name Ceruloplasmin Complement 3 Complement 4
Chemistry Abbreviation CER C3 C4

Measurement Principle Immunoturbidimetric Immunoturbidimetric Immunoturbidimetric
Measuring Points 0, 27 / 0, 10 0, 27 / 0, 10 0, 27 / 0, 10
Serum/Plasma 2 μL 2 μL (Pediatric = 2 μL) 2 μL (Pediatric = 2 μL)

Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 2 μL 1.6 μL (Pediatric = 1.6 μL) 1.6 μL (Pediatric = 1.6 μL)
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma 20-60 mg/dL 200-600 mg/L Adults and Adults and Adults and Adults and
children: children: children: children:
90-180 mg/dL 0.9-1.8 g/L 10-40 mg/dL 0.1-0.4 g/L
Serum/Plasma 6-200 mg/dL 60-2000 mg/L 15-500 mg/dL 0.15-5.0 g/L 8-150 mg/dL 0.08-1.50 g/L
Serum/Plasma ≤ 10% CV or ≤ 10% CV or ≤ 5% CV ≤ 5% CV ≤ 5% CV ≤ 5% CV

SD ≤ 2 mg/dL SD ≤ 20 mg/L
Reagent Volume

AU2700/AU5400
Heparin Heparin Heparin
ODR300371 ODR300371
Comment(s) 1
For Mastercurve enabled systems only 1
For Mastercurve enabled systems only
21
Proteins/Serology
Chemistry Name C-Reactive Protein C-Reactive Protein C-Reactive Protein, High Sensitivity
Chemistry Abbreviation CRP CRPN CRPHS

Measurement Principle Immunoturbidimetric Latex Particle Immunoturbidimetric Latex Particle Immunoturbidimetric
Reaction Type Fixed Fixed Fixed
Serum/Plasma 18 μL 2.0 μL 3.0 μL

Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 15 μL 1.6 μL 3.5 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma N/A < 5 mg/L N/A < 5 mg/L N/A < 1 mg/L
Serum/Plasma N/A 5-300 mg/L N/A 0.2-480 mg/L N/A 0.08-80 mg/L
Serum/Plasma N/A ≤ 5% CV or N/A ≤ 10% CV or N/A ≤ 10% CV or

SD ≤ 1 mg/L1 SD ≤ 1 mg/L1 SD ≤ 0.02 mg/L1
Reagent Volume
AU400/AU600/AU640 R1 = 70 μL, R2 = 30 μL R1 = 150 μL, R2 = 150 μL2 R1 = 75 μL, R2 = 75 μL

AU480/AU680/AU2700/AU5400 R1 = 47 μL, R2 = 20 μL R1 = 120 μL, R2 = 120 μL 2
R1 = 70 μL, R2 = 70 μL
Compatible Anticoagulants Heparin EDTA EDTA
Lithium Heparin Lithium Heparin
Calibrator Part Number ODR3021 ODC0026 ODC0027
Control Name ITA Control Serum 1, 2 & 3 ITA Control Serum 1, 2 & 3 CRP Latex Control Serum or
ITA Control Serum 1, 2 & 3
Control Part Number ODC0014, ODC0015, ODC0016 ODC0014, ODC0015, ODC0016 ODC0013 Level 1 & 2 or
ODC0014, ODC0015, ODC0016
Comment(s) 1
Use the greater number 1
Use the greater number 1
Use the greater number
2
Gently invert R2 5–10 times before
placing on instrument and weekly
thereafter
22
Proteins/Serology
Ferritin Ferritin
Chemistry Name Haptoglobin
Chemistry Abbreviation FERR FERR HAPT

Measurement Principle Latex Particle Immunoturbidimetric Latex Particle Immunoturbidimetric Immunoturbidimetric
Reaction Type Fixed Fixed End
Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 18 μL 6 μL 1.6 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma Male: Male: Male: Male: Adults: Adults:

20-250 ng/mL 20-250 μg/L 20-250 ng/mL 20-250 μg/L 30-200 mg/dL 0.3-2.0 g/L
Female: Female: Female: Female:
10-120 ng/mL 10-120 μg/L 10-120 ng/mL 10-120 μg/L
Serum/Plasma 8-450 ng/mL 8-450 μg/L 8-450 ng/mL 8-450 μg/L 30-400 mg/dL 0.3-4.0 g/L
Serum/Plasma ≤ 8% CV ≤ 8% CV ≤ 7% CV or ≤ 7% CV or ≤ 5% CV ≤ 5% CV
SD ≤ 3 ng/mL SD ≤ 3 μg/L
Reagent Volume
AU400/AU600/AU640 R1 = 120 μL, R2 = 25 μL1 R1 = 120 μL, R2 = 60 μL1 R1 = 165 μL, R2 = 45 μL

AU480/AU680/AU2700/AU5400 R1 = 120 μL, R2 = 25 μL 1
R1 = 120 μL, R2 = 60 μL 1
R1 = 132 μL, R2 = 36 μL
AU2700/AU5400
Calibration Frequency 14 days 30 days User defined
Lithium Heparin Lithium Heparin Heparin
Comment(s) Gently invert R2 5–10 times before
1
Gently invert R2 5–10 times before
1
placing on instrument and weekly placing on instrument and weekly

thereafter thereafter
23
Proteins/Serology
Chemistry Name Immunoglobulin A Immunoglobulin G Immunoglobulin M
Chemistry Abbreviation IgA IgG IgM

Measurement Principle Immunoturbidimetric Immunoturbidimetric Immunoturbidimetric
Primary Wavelength 600 nm Serum/Plasma: 600 nm 340 nm
CSF: 340 nm
Measuring Points 0, 27 / 0, 10 0, 23 / 0, 10 0, 27 / 0, 10
Sample Type Serum/Plasma Serum/Plasma/CSF Serum/Plasma
Serum/Plasma 2 μL (Pediatric = 2 μL) 2 μL (Pediatric = 2 μL) 2 μL (Pediatric = 2 μL)
Urine N/A N/A N/A
CSF N/A 10 μL N/A
AU2700/AU5400)
Serum/Plasma 1.6 μL (Pediatric = 1.6 μL) 1.6 μL (Pediatric = 1.6 μL) 1.6 μL (Pediatric = 1.6 μL)
Urine N/A N/A N/A
CSF N/A 10 μL N/A
Serum/Plasma Adults: Adults: 700-1600 mg/dL 7-16 g/L Adults: Adults:
70-400 mg/dL 0.7-4.0 g/L 40-230 mg/dL 0.4-2.3 g/L
Children: Children:
20-200 mg/dL 0.2-2.0 g/L
CSF N/A N/A 15–20 years: 15–20 years: N/A N/A
3.5 mg/dL ± 0.035 g/L ±
2.0 mg/dL 0.02 g/L
21–40 years: 21–40 years:
4.2 mg/dL ± 0.042 g/L ±
1.4 mg/dL 0.014 g/L
41–60 years: 41–60 years:
4.7 mg/dL ± 0.047 g/L ±
1.0 mg/dL 0.01 g/L
Serum/Plasma 10-700 mg/dL 0.1-7.0 g/L 75-3000 mg/dL 0.75-30 g/L 20-500 mg/dL 0.2-5.0 g/L
CSF N/A N/A 2-50 mg/dL 0.02-0.50 g/L N/A N/A
CSF N/A N/A ≤ 7.5% CV or ≤ 7.5% CV or N/A N/A
SD ≤ 0.5 mg/dL SD ≤ 0.005 g/L
Reagent Volume
AU400/AU600/AU640 R1 = 70 μL, R2 = 55 μL Serum: R1 = 110 μL, R2 = 100 μL R1 = 70 μL, R2 = 55 μL
CSF: R1 = 110 μL, R2 = 68 μL
AU480/AU680/AU2700/AU5400 R1 = 56 μL, R2 = 44 μL Serum: R1 = 88 μL (AU480: R1 = 87 μL), R1 = 56 μL, R2 = 44 μL
R2 = 80 μL
CSF: R1 = 110 μL, R2 = 68 μL
AU2700/AU5400
Calibration Frequency User defined Serum/Plasma: User defined User defined
CSF: 2 days
Heparin Heparin Heparin
Control Name ITA Control Serum 1, 2 & 3 Serum/Plasma: ITA Control Serum 1, ITA Control Serum 1, 2 & 3
2&3
CSF: N/A
Control Part Number ODC0014, ODC0015, ODC0016 Serum/Plasma: ODC0014, ODC0015, ODC0014, ODC0015, ODC0016
ODC0016
CSF: N/A
Comment(s)
24
Proteins/Serology
Chemistry Name Microalbumin Myoglobin Prealbumin
Chemistry Abbreviation MALB MYO PALB

Measurement Principle Immunoturbidimetric Latex Particle Immunoturbidimetric Immunoturbidimetric
Reaction Type End Fixed End
Measuring Points 0, 27 / 0, 10 12, 27 0, 27 / 0, 10
Sample Type Urine/CSF Serum Serum
Serum/Plasma N/A 11 μL 3 μL
Urine 10 μL N/A N/A
CSF 10 μL N/A N/A
AU2700/AU5400)
Serum/Plasma N/A 7 μL 2.4 μL
Urine 8 μL N/A N/A
CSF 8 μL N/A N/A
Serum/Plasma N/A N/A N/A Male: 19-92 μg/L 20-40 mg/dL 0.2-0.4 g/L
Female: 12-76 μg/L
Urine < 30 mg/24 hrs < 30 mg/24 hrs N/A N/A N/A N/A
CSF 3 months–4 years: 3 months–4 years: N/A N/A N/A N/A
0-45 mg/dL 0-450 mg/L
>4 years: > 4 years:
10-30 mg/dL 100-300 mg/L
Serum/Plasma N/A N/A N/A 30-800 μg/L 3-80 mg/dL 0.03-0.80 g/L
Urine 0.5-30 mg/dL 5-300 mg/L N/A N/A N/A N/A
CSF 0.5-30 mg/dL 5-300 mg/L N/A N/A N/A N/A
Serum/Plasma N/A N/A N/A ≤ 25% CV @ 30-100 μg/L ≤ 5% CV ≤ 5% CV
≤ 10% CV @ 101-349 μg/L
≤ 5% CV @ 350-800 μg/L
Urine ≤ 10% CV @ ≤ 10% CV @ N/A N/A N/A N/A
0.5-10 mg/dL 5-100 mg/L
≤ 5% CV @ ≤ 5% CV @
10-30 mg/dL 100-300 mg/L
CSF ≤ 10% CV @ ≤ 10% CV @ N/A N/A N/A N/A
0.5-10 mg/dL 5-100 mg/L
≤ 5% CV @ ≤ 5% CV @
10-30 mg/dL 100-300 mg/L
Reagent Volume
AU400/AU600/AU640 R1 = 150 μL, R2 = 50 μL R1 = 120 μL, R2 = 90 μL1 R1 = 150 μL, R2 = 65 μL
AU480/AU680/AU2700/AU5400 R1 = 120 μL, R2 = 40 μL R1 = 76 μL, R2 = 57 μL1 R1 = 120 μL, R2 = 52 μL
AU2700/AU5400
Compatible Anticoagulants N/A N/A N/A
Calibrator Part Number ODR3024 ODR3025 OSR3029
Control Name N/A N/A ITA Control Serum 1, 2 & 3
Control Part Number N/A N/A ODC0014, ODC0015, ODC0016
Comment(s) Gently invert R2 5–10 times before
1
placing on instrument and weekly

thereafter
25
Proteins/Serology
Chemistry Name Rheumatoid Factor Transferrin
Chemistry Abbreviation RF TRF

Measurement Principle Latex Particle immunoturbidimetric Immunoturbidimetric
Reaction Type Fixed End
Measuring Points 12, 19 0, 27 / 0, 10
Serum/Plasma 3 μL 2 μL (Pediatric = 2 μL)
Urine N/A N/A
CSF N/A N/A
AU2700/AU5400)
Serum/Plasma 2.6 μL 1.6 μL (Pediatric = 1.6 μL)
Urine N/A N/A
CSF N/A N/A
Serum/Plasma N/A ≤ 14 IU/mL Adults: Adults:
200-360 mg/dL 2.0-3.6 g/L
Children: Children:
0–−4 days: 0–−4 days:
130-275 mg/dL 1.30-2.75 g/L
3 months–10 years: 3 months–10 years:
203-360 mg/dL 2.03-3.6 g/L
CSF N/A N/A N/A N/A
Serum/Plasma N/A 10-120 IU/mL 75-750 mg/dL 0.75-7.50 g/L
CSF N/A N/A N/A N/A
Serum/Plasma N/A ≤ 10% CV ≤ 5% CV ≤ 5% CV
CSF N/A N/A N/A N/A
Reagent Volume
AU400/AU600/AU640 R1 = 120 μL, R2 = 40 μL1 R1 = 35 μL, R2 = 40 μL
AU480/AU680/AU2700/AU5400 R1 = 96 μL, R2 = 32 μL1 R1 = 28 μL, R2 = 32 μL
AU2700/AU5400
Calibration Frequency User defined User defined
Compatible Anticoagulants Citric Acid Plasma EDTA
Lithium Heparin Heparin
Sodium Heparin
Sodium/Potassium EDTA
Calibrator Part Number ODC0028 ODR3021
ODR300371
Control Name ITA Control Serum 1, 2 & 3 ITA Control Serum 1, 2 & 3
Control Part Number ODC0014, ODC0015, ODC0016 ODC0014, ODC0015, ODC0016
Comment(s) Gently invert R2 5–10 times
1
For use on Mastercurve enabled
1
before placing on instrument and systems only

weekly thereafter
26
Esoterics
Chemistry Name Cholinesterase Creatine Kinase MB D-Dimer
Chemistry Abbreviation CHE CK-MB DDIM

Measurement Principle GSCC 1994 Butyrylthiocholine CK IFCC method plus Immunoturbidimetric
Immuno-inhibition
Reaction Type Rate Rate Fixed
Sample Type Serum/Plasma Serum/Plasma Citrated Plasma
Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma Male: Male: Adults: Adults: N/A < 0.50 μg FEU/mL
4.62-11.5 kU/L 77-192 μkat/L < 24 U/L < 0.4 μkat/L
Female: Female:
3.93-10.8 kU/L 65-180 μkat/L
Serum/Plasma 1-15 kU/L 17-250 μkat/L 10-2000 U/L 0.17-33.3 μkat/L N/A 0.25-8.0 μg FEU/mL
Serum/Plasma ≤ 10% CV ≤ 10% CV ≤ 6.5% CV ≤ 6.5% CV N/A < 10% CV
Reagent Volume
AU2700/AU5400
Calibration Frequency Run in MB mode Run in MB mode 30 days
Compatible Anticoagulants Heparin Heparin Citrated Plasma
Lithium Heparin2
Calibrator Part Number 66300 ODR30034 ODR3033
Control Name Control Serum 1 & 2 CK-MB Control Levels 1 & 2 D-Dimer Control Levels 1 & 2
Control Part Number ODC0003, ODC0004 ODR30035, ODR30036 ODC0029
Comment(s) Mix R2 gently before use and on a
1
weekly basis thereafter

D-Dimer values in Heparin Plasma
2
are on average 16% higher over using

measuring range
27
Esoterics
Chemistry Name Hemoglobin A1c Lactate
Chemistry Abbreviation HbA1c LAC

Measurement Principle Turbidimetric Immuno-inhibition Enzymatic
Reaction Type THb: End Fixed
HbA1c: Fixed
Primary Wavelength THb: 600 nm 540 nm
HbA1c: 700 nm
Measuring Points THb: 0, 27 1, 15
HbA1c: 13, 22
Sample Type Pre-treated Whole Blood Plasma/CSF
Serum/Plasma N/A 2 μL
Urine N/A N/A
CSF N/A 2 μL
Other THb: 11.0 μL1
HbA1c: 3.5 μL1
Sample Size (AU480/AU680/ N/A
AU2700/AU5400)
Urine N/A N/A
CSF N/A
Other THb: 9.5 μL1
HbA1c: 3 μL1
Serum/Plasma N/A N/A 4.5-19.8 mg/dL 0.5-2.2 mmol/L
CSF N/A N/A Adult: 10-22 mg/dL Adult: 1.1-2.4 mmol/L
Other HbA1c DCCT: 4.0-6.2% HbA1c DCCT: 4.0-6.2%
HbA1c IFCC units: 2.0-4.4% HbA1c IFCC units: 2.0-4.4%
(recalculated using Master Equation) (recalculated using Master Equation)
Serum/Plasma N/A N/A 2-120 mg/dL 0.22-13.32 mmol/L
CSF N/A N/A 2-120 mg/dL 0.22-13.32 mmol/L
Other Total Hemoglobin: Total Hemoglobin:
4.4-14.3 mmol/L 7.10-23.06 g/dL
HbA1c: lowest to highest HbA1c: lowest to highest
calibrator value calibrator value
%HbA1c: 2.6%- 14.5% @ %HbA1c: 2.6%-14.5% @
THb ~9 mmol/L THb ~14.51 g/dL
Serum/Plasma N/A N/A ≤ 5% CV ≤ 5% CV
CSF N/A N/A ≤ 5% CV ≤ 5% CV
Other ≤ 5% CV ≤ 5% CV
Reagent Volume
AU400/AU600/AU640 THb R1 = 150 μL2 R1 = 200 μL
HbA1c R1 = 76 μL, R2 = 76 μL2
AU480/AU680/AU2700/AU5400 THb R1 = 130 μL 2 R1 = 160 μL
HbA1c R1 = 65 μL, R2 = 65 μL2
OSR0004 (2 x 250 tests)
AU2700/AU5400 OSR0004 (2 x 250 tests)
Liquid or Lyophilized Liquid Liquid/Lyophilized
Calibration Frequency 14 days 30 days
Compatible Anticoagulants K2 EDTA Sodium Fluoride -
NH4 Heparinized Whole Blood Potassium Oxalate
Calibrator Part Number ODR3032 66300
Control Name HbA1c Control Levels 1 & 2 Control Serum 1 & 2
Control Part Number ODC0022 ODC0003, ODC0004
Comment(s) 1
Whole blood values
2
HbA1c R1 should be mixed by inversion 5–10 times before
placing on board and weekly thereafter
Denaturant OSR0004
28
Therapeutic Drug Monitoring (TDM)
Chemistry Name Carbamazepine Digitoxin Digoxin
Chemistry Abbreviation CBZ DGT DIG

Measurement Principle Homogenous enzyme immunoassay Latex enhanced Immuno-inhibition Latex enhanced Immuno-inhibition
assay assay
Reaction Type Rate1 Fixed1 Fixed1
Measuring Points 24, 27 12, 27 12, 27 (AU400, AU640, AU600)
15, 27 (AU480, AU680, AU2700,
AU5400)
Sample Type Serum/Plasma Serum Serum
Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 1.6 μL 3 μL 6 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma 8-12 μg/mL 33.84-50.76 Effective levels: Effective levels: Effective levels: Effective levels:
μmol/L 10-30 ng/mL 13-39 nmol/L 0.8-2.0 ng/mL 1.0-2.6 nmol/L
Toxic levels: Toxic levels: Toxic levels: Toxic levels:
> 30 ng/mL > 39 nmol/L > 2.4 ng/mL > 3.1 nmol/L
Serum/Plasma 0.5-20 μg/mL 2.12-84.60 μmol/L 0-90 ng/mL 0-118 nmol/L 0-5 ng/mL 0.0-6.4 nmol/L
Serum/Plasma ≤ 7.5% CV or ≤ 7.5% CV or ≤ 6% CV or ≤ 6% or ≤ 6% CV or ≤ 6% CV or

SD ≤ 0.375 μg/mL SD ≤ 1.59 μmol/L SD ≤ 1.5 ng/mL SD ≤ 1.97 nmol/L SD ≤ 0.12 ng/mL SD ≤ 0.15 nmol/L
Reagent Volume

AU480/AU680/ R1 = 70 μL, R2 = 70 μL R1 = 105 μL, R2 = 64 μL R1 = 88 μL, R2 = 64 μL
AU2700/AU5400
AU2700/AU5400
Liquid or Lyophilized Liquid/Lyophilized Liquid Liquid
Compatible Anticoagulants Lithium Heparin N/A N/A
Sodium Heparin
Sodium EDTA
Calibrator Part Number ODC6411 ODC6403 ODC6404
Control Name N/A N/A N/A
Control Part Number N/A N/A N/A
Comment(s)
29
Chemistry Name Gentamicin Paracetamol Phenobarbital
Chemistry Abbreviation GENT PARA PHB

Measurement Principle Homogenous enzyme immunoassay Enzymatic Homogenous enzyme immunoassay
Reaction Type Rate1 End Rate1
Serum/Plasma 2 μL 7.5 μL 2 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Serum/Plasma 1.6 μL 6 μL 1.6 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma Peak 5.0-8.0 μg/mL Peak 10.45-16.72 10-30 mg/L 66-199 μmol/L 15-40 μg/mL 65-172 μmol/L
μmol/L
Serum/Plasma 0.24-12 μg/mL 0.5-25.1 μmol/L 15-378 mg/L 99-2500 μmol/L 1.2-80 μg/mL 5.17-344.8
μmol/L
Serum/Plasma ≤ 7.5% CV or ≤ 7.5% CV or ≤ 10% CV ≤ 10% CV ≤ 7.5% CV or ≤ 7.5% CV or

SD ≤ 0.18 μg/mL SD ≤ 0.38 μmol/L SD ≤ 0.9 μg/mL SD ≤ 3.88 μmol/L
Reagent Volume

AU2700/AU5400
AU2700/AU5400
Liquid or Lyophilized Liquid/Lyophilized Liquid/Lyophilized Liquid/Lyophilized
Calibration Frequency User defined 7 days User defined
Compatible Anticoagulants Lithium Heparin Lithium Heparin Lithium Heparin
Sodium Heparin Sodium Heparin
Sodium EDTA Sodium EDTA
Calibrator Part Number ODC6413 Included ODC6411
Control Name N/A Bio-Rad Lyphochek* Immunoassay plus N/A
Controls
Control Part Number N/A 370 N/A
Comment(s)
30
Chemistry Name Phenytoin Theophylline Valproic Acid
Chemistry Abbreviation PHT THEO VPA
Measurement Principle Homogenous enzyme immunoassay Homogenous enzyme immunoassay Homogenous enzyme immunoassay
Reaction Type Rate1 Rate1 Rate1
Serum/Plasma 2.5 μL 2 μL 2 μL
Urine N/A N/A N/A
CSF N/A N/A N/A
AU2700/AU5400)
Urine N/A N/A N/A
CSF N/A N/A N/A
Serum/Plasma Therapeutic: Therapeutic: Therapeutic: Therapeutic: 50-100 μg/mL 347-693 μmol/L

Adults:1 Adults:1 5-20 μg/mL1 28-111 μmol/L1
10-25 μg/mL 39.6-99 μmol/L Toxic: Toxic:
>20 μg/mL1 >111 μmol/L1
Serum/Plasma 0.6-40 μg/mL 2.4-158.4 μmol/L 0.8-40 μg/mL 4.44-222 μmol/L 3.0-150 μg/mL 20.8-1039.5
μmol/L
Serum/Plasma ≤ 7.5% CV or ≤ 7.5% CV or ≤ 7.5% CV or ≤ 7.5% CV or ≤ 7.5% CV or ≤ 7.5% CV or

SD ≤ 0.45 μg/mL SD ≤ 1.78 μmol/L SD ≤ 0.6 μg/mL SD ≤ 3.33 μmol/L SD ≤2.25 μg/mL SD ≤ 15.59 μmol/L
Reagent Volume

AU2700/AU5400
AU2700/AU5400
Compatible Anticoagulants Lithium Heparin Lithium Heparin Lithium Heparin
Sodium Heparin Sodium Heparin Sodium Heparin
Sodium EDTA Sodium EDTA Sodium EDTA
Calibrator Part Number ODC6411 ODC6411 ODC6411
Control Name N/A N/A N/A
Control Part Number N/A N/A N/A
Comment(s) 1
Depending on investigator 1
Depending on investigator
31
Drugs of Abuse Testing (DAT)
Amphetamines/Esctasy Amphetamines/Esctasy Amphetamines/Esctasy
Chemistry Name
(500 cutoff) (1000 cutoff) (Semi-quantitative)
Chemistry Abbreviation AMP AMP AMP
Measurement Principle Qualitative homogeneous enzyme Qualitative homogeneous enzyme Semi-quantitative homogeneous
immunoassay immunoassay enzyme immunoassay
Reaction Type Rate Rate Rate1
Sample Type Urine Urine Urine
Serum/Plasma N/A N/A N/A

Urine 4.0 μL 2.0 μL 2.0 μL
CSF N/A N/A N/A
AU2700/AU5400)
CSF N/A N/A N/A
Cutoff Level

Urine 500 μg/L 1000 μg/L N/A
CSF N/A N/A N/A
Analytical Range (UDR)

Urine User defined User defined User defined
CSF N/A N/A N/A
Precision Specification

Urine ≤ 10% CV ≤ 10% CV ≤ 10% CV
CSF N/A N/A N/A
Reagent Volume

AU2700/AU5400
Storage Temperature +2 to +8° C +2 to +8° C +2 to +8° C
Calibrator Part Number ODC6316 ODC6315 ODC6314, ODC6315, ODC6316,
ODC6317 & ODC6318 (ODC6326†)
Control Name DAU Speciality Control DAU Multi-drug Control DAU Speciality Control/Multi-drug
Control
Control Part Number ODC0007 ODC0006 ODC0007, ODC0006
Comment(s) † Applicable to Italy, Switzerland,
France, Germany and Austria
markets only
32
Barbiturate Barbiturate Barbiturate
Chemistry Name
Chemistry Abbreviation BAR BAR BAR
CSF N/A N/A N/A
AU2700/AU5400)
Urine 4.2 μL (AU2700/AU5400) 4.2 μL (AU2700/AU5400) 4.2 μL
6 μL (AU480/AU680) 6 μL (AU480/AU680)
CSF N/A N/A N/A
Cutoff Level
CSF N/A N/A N/A
CSF N/A N/A N/A
Urine ≤ 7.5% CV ≤ 7.5% CV ≤ 10% CV
CSF N/A N/A N/A
Reagent Volume
(AU 2700/AU 5400) (AU 2700/AU 5400)
R1 = 87 μL, R2 = 87 μL R1 = 87 μL, R2 = 87 μL
(AU 480/AU 680) (AU 480/AU 680)
AU2700/AU5400
ODC6317 & ODC6318 (ODC6326†)
Control
markets only
33
Benzodiazepine Benzodiazepine Benzodiazepine
Chemistry Name (200 cutoff) (300 cutoff) (Semi-quantitative)
Chemistry Abbreviation BNZ BNZ BNZ

Urine 2 μL 2 μL 2 μL
CSF N/A N/A N/A
AU2700/AU5400)
CSF N/A N/A N/A
Cutoff Level

CSF N/A N/A N/A

CSF N/A N/A N/A

Urine ≤ 7.5% CV ≤ 7.5% CV ≤ 10% CV
CSF N/A N/A N/A
Reagent Volume

AU2700/AU5400
ODC6317 & ODC6318 (ODC6326†)
Control
markets only
34
Cocaine Cocaine Cocaine
Chemistry Name
Chemistry Abbreviation COC COC COC

CSF N/A N/A N/A
AU2700/AU5400)
CSF N/A N/A N/A
Cutoff Level

CSF N/A N/A N/A

CSF N/A N/A N/A

Urine ≤ 7.5% CV ≤ 7.5% CV ≤ 10% CV
CSF N/A N/A N/A
Reagent Volume

AU480/AU680/ OSR6317 OSR6317 OSR6317
AU2700/AU5400
ODC6317 & ODC6318 (ODC6326†)
Control
markets only
35
EDDP EDDP
Chemistry Name
(100 cutoff) (Semi-quantitative)
Chemistry Abbreviation EDDP EDDP
Measurement Principle Qualitative homogeneous enzyme Semi-quantitative homogeneous
immunoassay enzyme immunoassay
Reaction Type Rate Rate1
Sample Type Urine Urine

Urine 8 μL 8 μL
CSF N/A N/A
AU2700/AU5400)
Urine 5.6 μL 5.6 μL
CSF N/A N/A
Cutoff Level

Urine 100 μg/L N/A
CSF N/A N/A

Urine User defined User defined
CSF N/A N/A

Urine ≤ 7.5% CV ≤ 10% CV
CSF N/A N/A
Reagent Volume


AU2700/AU5400
Liquid or Lyophilized Liquid/Lyophilized Liquid/Lyophilized
Compatible Anticoagulants N/A N/A
Calibrator Part Number ODC6315 or ODC6316 ODC6314, ODC6315 or ODC6316,
ODC6317, ODC6318
Control Name DAU Speciality Control/Multi-drug DAU Speciality Control/Multi-drug
Control Control
Comment(s)
36
Methadone Methadone
Chemistry Name
Chemistry Abbreviation MTD MTD

Urine 4 μL 4 μL
CSF N/A N/A
AU2700/AU5400)
CSF N/A N/A
Cutoff Level

Urine 300 μg/L N/A
CSF N/A N/A

CSF N/A N/A

Urine ≤ 7.5% CV ≤ 10% CV
CSF N/A N/A
Reagent Volume


AU2700/AU5400
Calibrator Part Number ODC6319 ODC6314, ODC6319, ODC6320
& ODC6321
Control Name DAU Multi-drug Control DAU Multi-drug Control
Control Part Number ODC0006 ODC0006
Comment(s)
37
Opiates Opiates
Chemistry Name
Chemistry Abbreviation OPI OPI

Urine 2 μL 2 μL
CSF N/A N/A
AU2700/AU5400)
CSF N/A N/A
Cutoff Level

Urine 300 μg/L N/A
CSF N/A N/A

CSF N/A N/A

Urine ≤ 7.5% CV ≤ 10% CV
CSF N/A N/A
Reagent Volume


AU2700/AU5400
Calibrator Part Number ODC6316 ODC6314, ODC6316, ODC6317
& ODC6318 (ODC6326†)
Control Name DAU Speciality Control DAU Speciality Control
Control Part Number ODC0007 ODC0007
markets only
38
THC THC THC
Chemistry Name
Chemistry Abbreviation THC THC THC

CSF N/A N/A N/A
AU2700/AU5400)
CSF N/A N/A N/A
Cutoff Level

CSF N/A N/A N/A

CSF N/A N/A N/A

Urine ≤ 7.5% CV ≤ 7.5% CV ≤ 10% CV
CSF N/A N/A N/A
Reagent Volume

AU2700/AU5400
ODC6324, ODC6325
Control Name DAU THC Controls DAU THC Controls DAU THC Controls
Comment(s)
39
Index LDL Cholesterol (LDL-C)................................................................... 12
Lipase (LIP)........................................................................................... 13
Alanine Aminotransferase (ALT)...........................................................4 Magnesium (MG)................................................................................. 14
Albumin (ALB)..........................................................................................4 Methadone 300 μg/L (MTD).............................................................. 37
Alkaline Phosphatase GSCC (ALP)....................................................5 Methadone SQ (MTD)......................................................................... 37
Alkaline Phosphatase IFCC (ALP).......................................................5 Microalbumin (MALB)......................................................................... 25
Alpha-1-Acidglycoprotein (AAG)....................................................... 19 Myoglobin (MYO)................................................................................. 25
Alpha -1-Antitrypsin (AAT).................................................................. 19 Opiates 300 μg/L (OPI)...................................................................... 38
Amphetamines/Ecstasy 500 μg/L (AMP)......................................... 32 Opiates SQ (OPI)................................................................................ 38
Amphetamines/Ecstasy 1000 μg/L (AMP)...................................... 32 Paracetamol (PARA)............................................................................ 30
Amphetamines/Ecstasy SQ (AMP)................................................... 32 Phenobarbital (PHB)........................................................................... 30
Amylase (CNP63) (AMY).......................................................................6 Phenytoin (PHT)................................................................................... 31
Amylase (IFCC-EPS) (AMY)..................................................................6 Phosphorus, Inorganic (PHOS)........................................................ 14
Anti-Streptolysin O (ASO).................................................................. 19 Prealbumin (PALB).............................................................................. 25
Apolipoprotein A1 (APO A1).............................................................. 20 Rheumatoid Factor (RF)...................................................................... 26
Apolipoprotein B (APO B).................................................................. 20 THC 25 μg/L (THC)............................................................................. 39
Aspartate Aminotransferase (AST).......................................................6 THC 50 μg/L (THC)............................................................................. 39
Barbiturate 200 μg/L (BAR)............................................................... 33 THC SQ (THC)..................................................................................... 39
Barbiturate 300 μg/L (BAR)............................................................... 33 Theophylline (THEO)........................................................................... 31
Barbiturate SQ (BAR)......................................................................... 33 Total Bilirubin (TBIL)............................................................................ 14
Benzodiazepine 200 μg/L (BNZ)...................................................... 34 Total Protein (TP).................................................................................. 15
Benzodiazepine 300 μg/L (BNZ)...................................................... 34 Transferrin (TRF).................................................................................. 26
Benzodiazepine SQ (BNZ)................................................................ 34 Triglyceride (TRIG)............................................................................... 15
Beta-2 Microglobulin (B2M).............................................................. 20 Unsaturated Iron Binding Capacity (UIBC)..................................... 16
Bicarbonate (CO2).................................................................................7 Unsaturated Iron Binding Capacity (UIBC)..................................... 16
Calcium Arsenazo (CALA).....................................................................7 Urea (UREA)......................................................................................... 17
Calcium oCPC (CA)...............................................................................7 Urea STAT (UREAS)............................................................................ 17
Carbamazepine (CBZ)........................................................................ 29 Uric Acid (UA)....................................................................................... 17
Ceruloplasmin (CER).......................................................................... 21 Urinary/CSF Protein (UCSFP)........................................................... 18
Cholesterol (CHOL)...............................................................................8 Valproic Acid (VPA).............................................................................. 31
Cholesterol (CHOL)...............................................................................8
Cholinesterase (CHE)......................................................................... 27
C-Reactive Protein (CRP).................................................................. 22
C-Reactive Protein (CRPN) .............................................................. 22
C-Reactive Protein, High Sensitivity (CRPHS)............................... 22
Cocaine 150 μg/L (COC)................................................................... 35
Cocaine 300 μg/L (COC).................................................................. 35
Cocaine SQ (COC)............................................................................. 35
Complement 3 (C3)............................................................................. 21
Complement 4 (C4)............................................................................. 21
Creatinine (CRE).....................................................................................8
Creatinine, Enzymatic (CREZ)..............................................................9
Creatine Kinase (CK)..............................................................................9
Creatine Kinase MB (CK-MB)........................................................... 27
D-Dimer (DDIM)................................................................................... 27
Digitoxin (DGT)..................................................................................... 29
Digoxin (DIG)........................................................................................ 29
Direct Bilirubin (DBIL)......................................................................... 10
EDDP 100 μg/L (EDDP)..................................................................... 36
EDDP SQ (EDDP)............................................................................... 36
Ferritin (FERR)...................................................................................... 23
Ferritin (FERR)...................................................................................... 23
Gamma-Glutamyltransferase (GGT)................................................. 10
Gentamicin (GENT)............................................................................. 30
Glucose (GLU)..................................................................................... 11
Glucose (GLU-S)................................................................................. 11
Haptoglobin (HAPT)............................................................................ 23
HDL Cholesterol (HDL-C).................................................................. 11
Hemoglobin A1c (IFCC) (HbA1c)..................................................... 28
Hydroxybutyrate Dehydrogenase (HBDH)....................................... 12
Immunoglobulin A (IgA)....................................................................... 24
Immunoglobulin G (IgG)..................................................................... 24
Immunoglobulin M (IgM)..................................................................... 24
Iron (IRON)............................................................................................ 12
Lactate Dehydrogenase (IFCC) (LDH)............................................. 13
Lactate Dehydrogenase (SCE) (LDH26)......................................... 13
40
Notes
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
41
Notes
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
42
Notes
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________
43
Laboratories around the world rely on Beckman Coulter’s promise of
quality, integrity and innovation. Our total laboratory solutions deliver
accurate information for medical research breakthroughs, clinical trials,
laboratory diagnostics and point-of-care testing. A partnership with
Beckman Coulter extends far beyond our products. With extensive
expertise in analyzing laboratory test processes, we collaborate with
you to understand your requirements and create flexible solutions that
meet your evolving needs.
W e’re better together. And together, we make a positive impact in

people’s lives.
Space for
FSC Logo
*All trademarks are the property of its respective owners
Beckman Coulter, the stylized logo, AU, AU400, AU480, AU600, AU640, AU680, AU2700, AU 2700Plus,
and AU5400 are registered trademarks of Beckman Coulter, Inc. Printed with soy ink
Australia, Gladesville (61) 2 9844 6000 Austria, Vienna (43) 662 857220 72 Canada, Mississauga (1) 905 819 1234
China, Shanghai (86) 21 3865 1000 Croatia, Zagreb (38) 51 489 9003 Czech Republic, Prague (420) 272 017 999
Eastern Europe, Middle East, North Africa, South West Asia: Switzerland, Nyon (41) 22 365 3707 France, Villepinte (33) 1 49 90 90 00
Germany, Krefeld (49) 2151 33 35 Hong Kong (852) 2814 7431 Hungary, Budapest (361) 25 09 330 India, Mumbai (91) 22 3080 5000
Italy, Cassina de’ Pecchi, Milan (39) 02 953921 Japan, Tokyo (81) 3 5530 8500 Korea, Seoul (82) 2 404 2146 Latin America (1) (305) 380 4709
Malaysia, Kuala Lumpur (60) 3 5621 4793 Mexico, Mexico City (001) 52 55 9183 2800 Netherlands, Woerden (31) 348 462462 Poland, Warszawa (48) 22 366 0180
Puerto Rico (787) 747 3335 Russia, Moscow (7) 495 9846730 Singapore (65) 6339 3633 South Africa/Sub-Saharan Africa, Johannesburg (27) 11 564 3203
Spain, Madrid (34) 91 3836080 Sweden, Bromma (46) 8 564 85 900 Switzerland, Nyon (41) 0800 850 810 Taiwan, Taipei (886) 2 2730 2500
Turkey, Istanbul (90) 216 570 17 17 UK, High Wycombe (44) 01494 441181 USA, Brea, CA (1) 800 352 3433, (1) 714 993 5321
B2010-11173-LC-2K www.beckmancoulter.com © 2010 Beckman Coulter, Inc. DIAG-PRINTED IN U.S.A.

Becknam-Ref Vrednosti

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Becknam-Ref Vrednosti

Uploaded by

Copyright:

Available Formats

AU reagent quick reference guide.

Reliable results, enhanced productivity.

BR-13843A Not for distribution in the U.S.

Serum/Plasma Male: Male: Adults: Adults:

Serum/Plasma 3-500 U/L 0.05-8.33 μkat/L 1.5-6.0 g/dL 15-60 g/L

Serum/Plasma ≤ 10% CV ≤ 10% CV ≤ 3% CV ≤ 3% CV

AU400/AU600/AU640 R1 = 100 μL, R2 = 50 μL R1 = 58 μL

Chemistry Abbreviation CO2 CALA CA

Chemistry Abbreviation CHOL CHOL CK

markets only gentle inversion

Chemistry Abbreviation CRE CREZ

Chemistry Abbreviation DBIL1 GGT

Chemistry Abbreviation GLU GLU-S HDL-C

Chemistry Abbreviation HBDH IRON LDL-C

TBIL-B need to be run

Chemistry Abbreviation TP TRIG

Chemistry Abbreviation UIBC UIBC

Serum/Plasma 155-355 μg/dL 27.8-63.6 μmol/L 155-300 μg/dL 27.8-53.7 μmol/L

Serum/Plasma 55-550 μg/dL 10-100 μmol/L 55-450 μg/dL 9.8-80.6 μmol/L

Serum/Plasma ≤ 5% CV ≤ 5% CV ≤ 10% CV ≤ 10% CV

AU400/AU600/AU640 R1 = 150 μL, R2 = 30 μL1 R1 = 150 μL, R2 = 30 μL1

AU400/AU600/AU640 OSR61205 (4 x 200 tests) OSR6124 (4 x 200 tests)

Chemistry Abbreviation UREA UREAS UA

Chemistry Abbreviation UCSFP

Serum/Plasma N/A N/A

Serum/Plasma N/A N/A

Serum/Plasma N/A N/A

AU400/AU600/AU640 OSR6170 (4 x 100 tests)

Chemistry Abbreviation AAG AAT ASO

Chemistry Abbreviation APO A1 APO B B2M

Serum/Plasma Male: Male: Male: Male: < 60 years: < 60 years:

Serum/Plasma ≤ 10% CV ≤ 10% CV ≤ 10% CV ≤ 10% CV ≤ 5% CV ≤ 5% CV

AU400/AU600/AU640 R1 = 65 μL, R2 = 65 μL R1 = 65 μL, R2 = 35 μL R1 = 100 μL, R2 = 80 μL

Chemistry Abbreviation CER C3 C4

Serum/Plasma 2 μL 2 μL (Pediatric = 2 μL) 2 μL (Pediatric = 2 μL)

Serum/Plasma ≤ 10% CV or ≤ 10% CV or ≤ 5% CV ≤ 5% CV ≤ 5% CV ≤ 5% CV

AU400/AU600/AU640 R1 = 180 μL, R2 = 50 μL R1 = 50 μL, R2 = 40 μL R1 = 50 μL, R2 = 40 μL

Chemistry Abbreviation CRP CRPN CRPHS

Serum/Plasma 18 μL 2.0 μL 3.0 μL

Serum/Plasma N/A ≤ 5% CV or N/A ≤ 10% CV or N/A ≤ 10% CV or

AU400/AU600/AU640 R1 = 70 μL, R2 = 30 μL R1 = 150 μL, R2 = 150 μL2 R1 = 75 μL, R2 = 75 μL

Chemistry Abbreviation FERR FERR HAPT

Serum/Plasma Male: Male: Male: Male: Adults: Adults:

AU400/AU600/AU640 R1 = 120 μL, R2 = 25 μL1 R1 = 120 μL, R2 = 60 μL1 R1 = 165 μL, R2 = 45 μL

placing on instrument and weekly placing on instrument and weekly

Chemistry Abbreviation IgA IgG IgM

Chemistry Abbreviation MALB MYO PALB

placing on instrument and weekly

Chemistry Abbreviation RF TRF

before placing on instrument and systems only

Chemistry Abbreviation CHE CK-MB DDIM

weekly basis thereafter

are on average 16% higher over using

Chemistry Abbreviation HbA1c LAC

Chemistry Abbreviation CBZ DGT DIG

Serum/Plasma ≤ 7.5% CV or ≤ 7.5% CV or ≤ 6% CV or ≤ 6% or ≤ 6% CV or ≤ 6% CV or

AU400/AU600/AU640 R1 = 87 μL, R2 = 87 μL R1 = 210 μL, R2 = 128 μL R1 = 176 μL, R2 = 128 μL

Chemistry Abbreviation GENT PARA PHB

Serum/Plasma ≤ 7.5% CV or ≤ 7.5% CV or ≤ 10% CV ≤ 10% CV ≤ 7.5% CV or ≤ 7.5% CV or

AU400/AU600/AU640 R1 = 100 μL, R2 = 75 μL R1 = 150 μL, R2 = 150 μL R1 = 120 μL, R2 = 120 μL

Serum/Plasma Therapeutic: Therapeutic: Therapeutic: Therapeutic: 50-100 μg/mL 347-693 μmol/L

Serum/Plasma ≤ 7.5% CV or ≤ 7.5% CV or ≤ 7.5% CV or ≤ 7.5% CV or ≤ 7.5% CV or ≤ 7.5% CV or

AU400/AU600/AU640 R1 = 87 μL, R2 = 87 μL R1 = 87 μL, R2 = 87 μL R1 = 85 μL, R2 = 64 μL